Risk-stratify with PCE / PREVENT; assign LDL target (very high risk < 55, high < 70, others per risk tier); statin of appropriate intensity + ezetimibe ± PCSK9i to reach target; address Lp(a) and triglycerides separately.
Authored pathway active · cardio.dyslipidemia.outpatient.outpatient
Risk-stratify with PCE / PREVENT; assign LDL target (very high risk < 55, high < 70, others per risk tier); statin of appropriate intensity + ezetimibe ± PCSK9i to reach target; address Lp(a) and triglycerides separately.
Guidelines: ACC/AHA 2025 Multisociety Guideline on Management of Blood Cholesterol · ESC/EAS 2019 Dyslipidaemia Guideline + 2024 update · NLA Lp(a) Statement 2024
Phenotypes (4)
- Very High ASCVD Risk (ASCVD event or >20% 10-year risk)
- High ASCVD Risk (10-year risk 7.5–19.9%)
- Familial Hypercholesterolemia (FH)
- Severe Hypertriglyceridemia (TG > 500 mg/dL)
Red flags (1)
- Escalate if the HLD presentation becomes unstable.HIGH
Pathway-scoped symptom and exam intake
Test this pathway's ROS and differential links
Uses LR engine cardio.lipid.core.v1, then routes suggested engines into the workspace.
19-panel workspace
cardio.dyslipidemia.outpatient · OutpatientStart patient workup
Open a scratch or linked encounter, add active problems, then keep labs, fluids, acid-base, and electrolyte tools beside the main workspace instead of losing context.
Encounter and problems
No encounter open. Add a problem to create a scratch encounter when none is open.
Multi-window tools
Unified
labs + fluids + acid-base
Labs
fast lab analyzer
Fluid
resuscitation and balance
Electrolytes
Na/K/Mg/Phos/Ca
ABG/VBG
compensation and mixed disorders
Popular entry points
6 quick-startsOr jump straight to the atlas
The Engine Atlas covers every authored disease package with setting chips and pathway badges. Open any engine to load its 19-panel workspace, backed by phenotype-aware reasoning and monitored by the Flow Assistant.